*Staphylococcus aureus* is among the most common and devastating human bacterial pathogens, causing 20%--30% of bloodstream and surgical site infections, as well as up to half of bone and joint infections \[[@CIT0001]\]. The key to the success of *S. aureus* as a pathogen is its ability to develop antimicrobial resistance. The emergence of penicillinase-producing *S. aureus* strains occurred shortly after the introduction of penicillin for clinical use, and by the 1970s the vast majority of *S. aureus* infections were penicillin resistant \[[@CIT0001]\]. Likewise, methicillin (oxacillin) resistance among *S. aureus* was reported in the early 1960s, after the introduction of methicillin \[[@CIT0006]\]. Since that time, the continued emergence and spread of methicillin-resistant *S. aureus* (MRSA) has complicated the antimicrobial treatment of *S. aureus* \[[@CIT0001], [@CIT0007], [@CIT0008]\]. MRSA strains are not only resistant to nearly all beta-lactams, but many have developed resistance to multiple other antimicrobial classes \[[@CIT0009]\].

The epidemiology of MRSA infections has been characterized by sequential "waves" of epidemic clones spreading across geographic regions, nations, and continents \[[@CIT0001], [@CIT0007]\]. The result has been substantial regional variation in MRSA rates. One recent wave of resistance has been the global increase in community-associated strains of MRSA (CA-MRSA), including the emergence in the 1990s of pulsed-field-type USA300 (clonal complex \[CC\] 8) in the United States, followed by the spread of this strain across that country, around the world, and into health care (HC) environments \[[@CIT0007], [@CIT0010], [@CIT0011]\]. Of note, USA300 and other strains of CA-MRSA are usually resistant to fewer other classes than HC-adapted strains (eg, USA100). Therefore, when they replace older MRSA clones, the result may be reduced rates of resistance to other antibiotic classes among MRSA.

As MRSA has become endemic, the use of vancomycin for therapy of invasive MRSA infections has increased, along with concerns about development of vancomycin resistance among MRSA \[[@CIT0012]\]. Although most MRSA isolates (\>99%) remain susceptible to vancomycin, several reports suggest that increased vancomycin minimum inhibitory concentrations (MICs), even within the susceptible range, may predispose to treatment failure \[[@CIT0013]\], and some investigators have also reported vancomycin "MIC creep" among MRSA isolates that could result in increased frequency of vancomycin treatment failure \[[@CIT0014]\]. During the same time period, several agents with in vitro activity against MRSA have been introduced \[[@CIT0015], [@CIT0016]\]. These agents are being used increasingly as alternatives to vancomycin for treating some serious MRSA infections.

To continue to monitor trends in the proportion of *S. aureus* infections due to MRSA, the activity of vancomycin against clinical isolates of MRSA over time, and the activity of other antimicrobial classes and newer agents against *S. aureus*, ongoing prospective surveillance is critical. The SENTRY Antimicrobial Surveillance Program has been ongoing for 20 years, collecting consecutive, clinically significant isolates of bacterial pathogens (including *S. aureus*) that cause diseases in North America, Europe, Latin America, and the Asia-Pacific region. Strengths of the program include using reference in vitro susceptibility testing methods at a central laboratory, providing consistency over time in MIC determination, and the breadth of the program. We can now report trends in antimicrobial resistance among almost 200 000 *S. aureus* isolates submitted to the SENTRY Program during the 20 years since its inception in 1997.

METHODS {#s5}
=======

The SENTRY Antimicrobial Surveillance Program is a sentinel surveillance program for tracking antimicrobial occurrences and resistance worldwide via a global network of medical centers. From 1997 to 2016, each participating SENTRY Program center submitted bacterial isolates and clinical data for consecutive episodes of bacteremia (bloodstream infections \[BSIs\]), pneumonia in hospitalized patients (PIHP), intra-abdominal infections (IAIs), urinary tract infections (UTIs), and skin and skin structure infections (SSSIs). Isolate identification was confirmed at the central reference laboratory using conventional and proteomic methods (*S. aureus* identification was confirmed by the coagulase test from 1997 to 2012 and by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) from 2012 to 2016). From 1997 to 2016, the SENTRY Program collected \>750 000 clinical isolates from \>400 centers worldwide. This report describes results from the 191 460 *S. aureus* isolates collected from 427 SENTRY Program participating centers in North America, Latin America, Europe, and the Asia-Pacific region between January 1997 and December 2016. For designating regional differences within the United States, census division designations were applied \[[@CIT0017]\]. When the sample collection date was ≥3 days after the admission date, we designated the infection episode to be nosocomial (vs community onset).

Antimicrobial Susceptibility Testing {#s6}
------------------------------------

All isolates were tested for susceptibility against \>20 antimicrobial agents each year at the central laboratories, using reference broth microdilution methods and interpretive MIC breakpoints, as described by the Clinical and Laboratory Standards Institute (CLSI) \[[@CIT0018]\]. Food and Drug Administration breakpoints were used if CLSI breakpoints were not available, as well as those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@CIT0019]\]. Quality control was performed as recommended by the CLSI, and results were all within established ranges \[[@CIT0020]\].

RESULTS {#s7}
=======

Of the 191 460 *S. aureus* isolates submitted during the 20-year surveillance period, a total of 77 146 (40.3%) were MRSA. The highest rates (%) of MRSA were among nosocomial isolates, those from patients \>80 years of age, and those from PIHP or UTI episodes ([Table 1](#T1){ref-type="table"}). The percentage of MRSA among all *S. aureus* isolates varied geographically, from 26.8% in Europe to 47.0% in North America ([Figure 1](#F1){ref-type="fig"}). Within the United States, the MRSA rate was highest in the Southern census divisions and lowest in the Mountain division ([Figure 2](#F2){ref-type="fig"}). The overall MRSA rate increased from 33.1% in 1997--2000 to a high of 44.2% in 2005--2008, and has since declined to 42.3% and 39.0% in 2009--2012 and 2013--2016, respectively. *S. aureus* BSI isolates had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005--2008 and then declining ([Figure 3](#F3){ref-type="fig"}).

###### 

Methicillin Resistance by Specimen Source, Health Care Association, and Age (SENTRY Program, 1997--2016)

  Variable                  No. Tested   \% MRSA
  ------------------------- ------------ ---------
  Specimen source                        
   BSI                      68 564       37.1
   PIHP                     34 029       45.6
   SSSI                     70 757       41.0
   UTI                      2916         51.9
  Health care association                
   Community onset          86 366       36.8
   Nosocomial               46 086       47.0
  Age, y                                 
   ≤10                      19 109       37.2
   11--20                   10 425       33.9
   21--30                   13 048       37.7
   31--40                   15 428       38.1
   41--50                   21 690       38.7
   51--60                   27 120       40.2
   61--70                   27 174       41.5
   71--80                   24 502       45.1
   \>80                     17 371       48.0

Abbreviations: BSI, bloodstream infection; MRSA, methicillin-resistant *Staphylococcus aureus;* PIHP, pneumonia in hospitalized patients; SSSI, skin and skin structure infection; UTI, urinary tract infection; y, years.

![Percent MRSA by region. Abbreviation: MRSA, methicillin-resistant *Staphylococcus aureus.*](ofy27001){#F1}

![Methicillin resistance by US census division: SENTRY Program, 1997--2016. Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; 1, New England; 2, Middle Atlantic; 3, East North Central; 4, West North Central; 5, South Atlantic; 6, East South Central; 7, West South Central; 8, Mountain; 9, Pacific; 10, Total.](ofy27002){#F2}

![SENTRY Program 20-year trends in percentage of *Staphylococcus aureus* BSI isolates that are MRSA. Abbreviations: BSI, bloodstream infection; MRSA, methicillin-resistant *Staphylococcus aureus*.](ofy27003){#F3}

In vitro susceptibility to penicillin among methicillin-susceptible *S. aureus* (MSSA) increased over time ([Table 2](#T2){ref-type="table"}). Similarly, several other older antimicrobial agents exhibited increased activity (% susceptible) over time against MRSA ([Table 2](#T2){ref-type="table"}).

###### 

Temporal Trend in Percent Susceptibility to Selected Older Antimicrobials Among *S. aureus* Isolates, Stratified by Methicillin Resistance (SENTRY Program, 1997--2016)

                   \% Susceptible by Time Interval                         
  ---------------- --------------------------------- ---- ---- ----- ----- ----
  MSSA                                                                     
   Penicillin      14                                19   20   23    26    21
   Erythromycin    73                                80   78   73    74    75
   Clindamycin     96                                96   96   95    96    96
   Doxycycline     98                                99   98   99    99    99
   Tetracycline    93                                94   94   94    95    94
   Ciprofloxacin   95                                93   91   90    90    91
   Gentamicin      97                                97   97   97    98    97
   TMP-SMX         100                               98   98   99    99    99
   Rifampin        99                                99   99   ---   ---   99
  MRSA                                                                     
   Erythromycin    7                                 9    12   15    18    13
   Clindamycin     23                                33   53   63    70    55
   Doxycycline     71                                84   91   94    96    90
   Tetracycline    61                                77   83   86    90    83
   Ciprofloxacin   10                                10   20   25    28    20
   Gentamicin      46                                65   77   83    89    77
   TMP-SMX         72                                85   91   96    97    91
   Rifampin        78                                86   88   ---   ---   83

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S. aureus*; TMP-SMX, trimethoprim-sulfamethoxazole.

Vancomycin activity against *S. aureus* remained stable: overall MIC~90~ at 1 mg/L, with 100% susceptibility in 2016 ([Table 3](#T3){ref-type="table"}). No increase across time was observed in the percentage of *S. aureus* (including MRSA) with a vancomycin MIC \>1 mg/L (\<3% overall and \<1% during the 2013--2016 time period), and we did not observe a consistent or sustained increase in the percentage of MRSA with a vancomycin MIC of 1 mg/L. Notably, only 1 *S. aureus* isolate with an MIC \>4 mg/L (MIC, 8 mg/L) was detected during this 20-year surveillance program using reference MIC methods.

###### 

Vancomycin MIC Distributions of *S. aureus* Isolates Collected From Participating SENTRY Program Centers, 1997--2016

                    No. (Cumulative %) at Each Vancomycin MIC, mg/L                                                                              
  ------- --------- ------------------------------------------------- ----------- --------------- ---------------- --------------- ------------- -----------
  MSSA    114 297   49 (0.1)                                          243 (0.4)   28 862 (25.5)   83 549 (98.6)    1569 (\>99.9)   25 (100.0)    
  MRSA    77 145    18 (\<0.1)                                        220 (0.3)   15 807 (20.8)   57 319 (95.1)    3745 (\>99.9)   35 (\>99.9)   1 (100.0)
  Total   191 442   67 (\<0.1)                                        463 (0.3)   44 669 (23.6)   140 868 (97.2)   5314 (\>99.9)   60 (\>99.9)   1 (100.0)

Abbreviations: MIC, minimum inhibitory concentration; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S. aureus.*

Several agents introduced during the surveillance period exhibited in vitro potency against MRSA and isolates with a vancomycin MIC \>1 mg/L ([Table 4](#T4){ref-type="table"}). For example, \>98% of such isolates were susceptible in vitro to daptomycin, dalbavancin, oritavancin, telavancin, linezolid, tedizolid, and tigecycline.

###### 

Activity of Selected Antimicrobial Agents When Tested Against *S. aureus*, Stratified by Methicillin Resistance and for Isolates With Vancomycin MIC at \>1 mg/L (SENTRY Program, 1997--2016)

                                                                          CLSI^a^           
  ---------------------------- --------- -------- ------- --------------- --------- ------- -------
  MSSA                         114 300                                                      
   Ceftaroline                 58 938    0.25     0.25    ≤0.06--1        100.0     0.0     0.0
   Dalbavancin                 92 584    0.06     0.06    ≤0.03--\>0.25   \>99.9            
   Daptomycin                  94 022    0.25     0.5     ≤0.12--4        \>99.9            
   Delafloxacin                18 033    ≤0.004   0.015   ≤0.004--\>1     98.1      0.9     0.9
   Levofloxacin                103 405   ≤0.5     ≤0.5    ≤0.5--\>4       92.3      0.5     7.1
   Linezolid                   110 519   1        2       ≤0.12--\>8      \>99.9            \<0.1
   Oritavancin                 50 013    0.03     0.06    ≤0.008--0.5     99.7              
   Quinupristin-dalfopristin   68 250    ≤0.5     ≤0.5    ≤0.5--\>2       99.9      0.1     \<0.1
   Tedizolid                   22 987    0.12     0.12    ≤0.008--0.5     100.0     0.0     0.0
   Teicoplanin                 114 285   ≤2       ≤2      ≤2--\>8         \>99.9            
   Telavancin                  46 041    0.03     0.06    ≤0.015--0.25    \>99.9            
   Tigecycline                 93 850    ≤0.12    0.25    ≤0.12--1        \>99.9            
   Vancomycin                  114 297   1        1       ≤0.12--4        \>99.9    \<0.1   0.0
  MRSA                         77 146                                                       
   Ceftaroline                 40 731    1        1       0.015--\>8      91.6      8.2     0.2
   Dalbavancin                 65 302    0.06     0.06    ≤0.03--\>0.25   \>99.9            
   Daptomycin                  66 380    0.25     0.5     ≤0.12--4        99.9              
   Delafloxacin                10 243    0.12     1       ≤0.004--\>1     74.3      12.3    13.4
   Levofloxacin                72 075    \>4      \>4     ≤0.5--\>4       23.4      1.7     75.0
   Linezolid                   75 780    1        2       ≤0.25--\>8      99.9              0.1
   Oritavancin                 35 262    0.03     0.06    ≤0.008--0.5     99.6              
   Quinupristin-dalfopristin   46 141    ≤0.5     1       ≤0.5--\>2       99.5      0.3     0.2
   Tedizolid                   13 828    0.12     0.12    0.015--\>1      \>99.9    0.0     \<0.1
   Teicoplanin                 77 130    ≤2       ≤2      ≤2--\>16        \>99.9    \<0.1   \<0.1
   Telavancin                  31 000    0.03     0.06    ≤0.015--0.25    \>99.9            
   Tigecycline                 65 977    ≤0.12    0.25    ≤0.12--4        99.8              
   Vancomycin                  77 145    1        1       ≤0.12--4        \>99.9    \<0.1   0.0
  Vancomycin (MIC ≥2 mg/L)     5375                                                         
   Ceftaroline                 1332      0.5      2       0.015--2        86.2      13.8    0.0
   Dalbavancin                 3318      0.06     0.12    ≤0.03--\>0.25   99.5              
   Daptomycin                  3479      0.5      1       ≤0.12--4        98.3              
   Delafloxacin                103       0.12     1       ≤0.004--\>1     71.8      12.6    15.5
   Levofloxacin                4549      \>4      \>4     ≤0.5--\>4       32.1      1.2     66.7
   Linezolid                   5093      1        2       ≤0.25--\>8      99.9              0.1
   Oritavancin                 1024      0.06     0.12    ≤0.008--0.5     98.0              
   Quinupristin-dalfopristin   4506      ≤0.5     1       ≤0.5--\>2       98.4      0.7     0.9
   Tedizolid                   190       0.12     0.25    0.03--0.25      100.0             
   Teicoplanin                 5374      ≤2       4       2--\>16         99.6      0.3     0.1
   Telavancin                  867       0.06     0.06    ≤0.015--0.12    100.0             
   Tigecycline                 3497      ≤0.12    0.5     ≤0.12--1        98.7              

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; I, intermediate; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *S. aureus;* R, resistance; S, susceptible.

^a^Criteria as published by CLSI 2018.

DISCUSSION {#s8}
==========

Although many antimicrobial resistance surveillance programs exist, most are limited to a single country or region \[[@CIT0004], [@CIT0021]\] and focus exclusively on 1 infection site or type (eg, bloodstream infections, nosocomial infections). Moreover, many programs gather susceptibility data from participating sites but do not confirm susceptibility or organism identification results. The SENTRY Program is a large global surveillance program that monitors pathogens from consecutive episodes of infection at multiple body sites, providing a very large number of isolates tested by a central monitoring reference laboratory \[[@CIT0024]\]. The consecutive nature of SENTRY Program collection allows for the inference of prevalence at each site and, to some degree, for that region. These strengths provide the opportunity to examine on a large scale the trends that have been reported from various geographic areas.

The major trend noted in our 20-year *S. aureus* surveillance was that the rise of MRSA as a proportion of all *S. aureus* infections peaked a decade ago, after which the MRSA rates have declined. This is consistent with several other regional and national surveillance programs that observed reductions in MRSA infections, or in the proportion of *S. aureus* that are MRSA, beginning during 2000--2010 in the United States \[[@CIT0002], [@CIT0021]\], the United Kingdom \[[@CIT0025]\], and Europe \[[@CIT0022]\]. This decline coincided with increased focus on infection prevention in medical centers generally, and MRSA in particular in some health systems \[[@CIT0026]\]. However, the fact that the decline occurred in all surveillance regions and among both community-onset and hospital-onset infections suggests that factors other than health care facility infection control interventions may be responsible, including bacterial factors associated with the continued evolution of this common human pathogen (eg, the rise and fall of successful MRSA clones across human populations). Regional variation in antibiotic prescribing and socioeconomic factors may also be associated with MRSA infection rates, as recently described by Andreatos and colleagues \[[@CIT0027]\]. Ongoing surveillance and further research are required to detect future waves of resistance among *S. aureus* and to help determine in more detail what factors may be associated with MRSA epidemics, as well as with periods of decline in MRSA incidence or prevalence \[[@CIT0028]\].

The susceptibility of MRSA isolates to several older antimicrobial agents has also increased across the last 2 decades, a possible result of the epidemic spread of MRSA clones (eg, USA300) that are more susceptible to these agents \[[@CIT0001], [@CIT0007], [@CIT0011]\]. This favorable trend provides options for MRSA therapy from among well-established older agents (eg, clindamycin, trimethoprim-sulfamethoxazole, tetracyclines) \[[@CIT0029]\]. However, for serious invasive MRSA infections, including bacteremia, vancomycin remains the most commonly used antimicrobial for treatment, despite concerns about efficacy \[[@CIT0029]\], the emergence of resistance \[[@CIT0012]\], and the MIC creep phenomenon \[[@CIT0014]\]. Regarding the emergence of resistance and MIC creep, results from this large longitudinal study are reassuring: we find no evidence to support MIC creep, consistent with a recently published meta-analysis \[[@CIT0014]\], and confirm that \>99.9% of both MRSA and MSSA isolates have vancomycin MICs of ≤2 mg/L.

Several newer alternatives to vancomycin among other antimicrobial classes were introduced during the 20-year time period of this surveillance program, providing an expanded armamentarium against MRSA. Although the number of isolates tested against these agents varies based upon when they were added to our surveillance, ceftaroline, daptomycin, dalbavancin, oritavancin, telavancin, linezolid, tedizolid, and tigecycline all exhibit good in vitro activity against *S. aureus*, including isolates with vancomycin MICs of 2 mg/L or greater. More experience will be required to demonstrate the efficacy of some of these agents in clinical settings, in which vancomycin remains a default choice (eg, invasive and high-inoculum MRSA infections, including bacteremia and endocarditis).

Among MSSA isolates, which still cause the majority of *S. aureus* infections, rates of susceptibility to non-beta-lactam agents remain stable and high. Of particular interest, penicillin susceptibility among MSSA isolates has steadily increased, from 14% in 1997--2000 to 26% in 2013--2016. Other investigators have noted similar findings, from single centers to national surveillance programs \[[@CIT0030]\]. With the caveat that laboratory confirmation of susceptibility is required given the limitations of phenotypic detection of penicillin resistance in *S. aureus* \[[@CIT0035]\], our findings serve as a reminder that penicillin may be an option for a nontrivial number of serious *S. aureus* infections \[[@CIT0036]\].

The *S. aureus* surveillance data we present in this report have limitations. As a sentinel network that collects pathogens from select medical centers, the SENTRY Program does not provide population-based information about the incidence of infections in a given region. For example, it is possible for the proportion of *S. aureus* isolates that are MRSA to be falling while overall infection rates due to *S. aureus* or MRSA are increasing. In addition, not all sentinel medical centers participated in each year of the 20-year surveillance program. As participating centers leave the program, additional centers from that region may be added, with the goal of maintaining a robust and broadly representative sample from as many countries and regions as possible. Furthermore, regions of the world with limited resources for clinical laboratory support are also underrepresented or not represented (eg, Africa) in this report. Finally, we do not present molecular typing or sequencing data in this report to investigate some of the trends noted (eg, emergence over time of various epidemic clones of MRSA).

Nonetheless, the 2-decade surveillance period and international scope of this study provide important insights into trends in antimicrobial resistance among *S. aureus*, most of which do not fit neatly into a narrative of relentless increases in resistance. The proportion of clinical *S. aureus* isolates represented by MRSA has been declining for the past decade, resistance to several older drug classes among MRSA has been decreasing, vancomycin in vitro activity remains stable, and penicillin susceptibility among MSSA isolates has been increasing. Meanwhile, the number of available options for treatment of MRSA infections has expanded with the release of several new compounds with excellent in vitro activity. Despite these favorable findings, MRSA remains a common and devastating pathogen that is frequently refractory to therapy and for which improved prevention and treatment approaches are needed. Ongoing surveillance is important to help inform the development of these approaches.
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